{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:57:31Z","timestamp":1792040251141,"version":"4.4.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The expanded use of long-term antiretroviral treatments in infected children may exacerbate the problem of drug resistance mutations selection, which can compromise treatment efficiency.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>We describe the temporal trends of HIV drug resistance mutations and the HIV-1 variants during 23 years (1993 to March 2016) in the Madrid cohort of HIV-infected children and adolescents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We selected patients with at least one available HIV-1 <jats:italic toggle=\"yes\">pol<\/jats:italic> sequence\/genotypic resistance profile, establishing different groups according to the sampling year of first resistance data. We determined the prevalence of transmitted drug resistance mutations or acquired drug resistance mutations (DRM), the drug susceptibility among resistant viruses and HIV-1 variants characterized by phylogeny across time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 245 pediatric patients were selected, being mainly female, Spanish native, perinatally infected and carrying HIV-1 subtype B. At first sampling, most pediatric patients were on antiretroviral therapy and heavily pretreated. During 1993 to 2016, transmitted drug resistance mutations was found in 13 (26%) of 50 naive children [non-nucleoside reverse transcriptase inhibitors (NNRTI), 14.6%; nucleoside reverse transcriptase inhibitors (NRTI), 10.4%; protease inhibitors, 8.7%]. DRM appeared in 139 (73.2%) of 190 pretreated patients (NRTI, 64.5%; NNRTI, 36%; protease inhibitors, 35.1%). DRM to NNRTI was higher in last 5 years. Non-B variants infected 14.5% of children and adolescents of the Madrid Cohort, being mainly intersubtype recombinants (76.5%), including complex unique recombinant strains. They caused 3.4% infections before 2000, rising to 85.7% during 2011 to 2016.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Periodic surveillance resistance and molecular epidemiology studies in long-term pretreated HIV-infected pediatric populations are required to optimize treatment regimens. Results will permit a better understanding of long-time dynamics of viral resistance and HIV-1 variants in Spain.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001760","type":"journal-article","created":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T04:18:30Z","timestamp":1507349910000},"page":"e48-e57","source":"Crossref","is-referenced-by-count":15,"title":["Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis"],"prefix":"10.1097","volume":"37","author":[{"given":"Patricia","family":"Rojas S\u00e1nchez","sequence":"first","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Jim\u00e9nez De Ory","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Prieto","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rojo","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pepa","family":"Mellado","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Navarro","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Tomas","family":"Ramos","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1frica","family":"Holgu\u00edn","sequence":"additional","affiliation":[{"name":"Medicine Department, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230913","doi-asserted-by":"crossref","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/513871","article-title":"Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.","volume":"195","author":"Persaud","year":"2007","journal-title":"J Infect Dis"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11539260-000000000-00000","article-title":"Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.","volume":"50","author":"Rakhmanina","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3851\/IMP2320","article-title":"Determinants of HIV drug resistance and public health implications in low- and middle-income countries.","volume":"17","author":"Bertagnolio","year":"2012","journal-title":"Antivir Ther"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(11)60208-0","article-title":"Risk of triple-class virologic failure in children with HIV: a retrospective cohort study PLATO II.","volume":"377","author":"Castro","year":"2011","journal-title":"Lancet"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1586\/14787210.2015.1068117","article-title":"Tackling virological failure in HIV-infected children living in Africa.","volume":"13","author":"Jenabian","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/jac\/dku104","article-title":"Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.","volume":"69","author":"Rojas S\u00e1nchez","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eimc.2011.09.007","article-title":"[New diagnosis of HIV infection in children].","volume":"30","author":"Guill\u00e9n","year":"2012","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R11-20230913","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e32833a0993","article-title":"Late postnatal HIV infection in children born to HIV-1-infected mothers in a high-income country.","volume":"24","author":"Frange","year":"2010","journal-title":"AIDS"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/INF.0b013e3182678c7c","article-title":"Dynamics of drug resistance prevalence and susceptibility in the Madrid cohort of HIV-1-infected children: 1993\u20132010 analysis.","volume":"11","author":"de Mulder","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R14-20230913","doi-asserted-by":"crossref","first-page":"e52155","DOI":"10.1371\/journal.pone.0052155","article-title":"High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain.","volume":"7","author":"de Mulder","year":"2012","journal-title":"PLoS One"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"e0173168","DOI":"10.1371\/journal.pone.0173168","article-title":"Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000\u20132014.","volume":"12","author":"Rojas S\u00e1nchez","year":"2017","journal-title":"PLoS One"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"R17-20230913","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1.","volume":"23","author":"Wensing","year":"2015","journal-title":"Top Antivir Med"},{"key":"R18-20230913","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/INF.0b013e3181646d6f","article-title":"HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.","volume":"27","author":"Chakraborty","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-12-317","article-title":"High viremia and low level of transmitted drug resistance in anti-retroviral therapy-na\u00efve perinatally-infected children and adolescents with HIV-1 subtype C infection.","volume":"12","author":"Neogi","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1097\/INF.0b013e31827fb2d1","article-title":"Effectiveness of first-line antiretroviral therapy and acquired drug resistance among HIV-1-infected children in India.","volume":"32","author":"Shet","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1097\/INF.0b013e3182684d8e","article-title":"Prevalence of transmitted HIV-1 drug resistance mutations in children and adolescents in S\u00e3o Paulo, Brazil.","volume":"31","author":"Almeida","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1590\/S0074-02762003000600021","article-title":"Human immunodeficiency virus type 1: drug resistance in treated and untreated Brazilian children.","volume":"98","author":"Simonetti","year":"2003","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"407476","DOI":"10.1155\/2010\/407476","article-title":"HIV drug resistance-associated mutations in antiretroviral na\u00efve HIV-1-infected latin American children.","volume":"2010","author":"Soto-Ramirez","year":"2010","journal-title":"Adv Virol"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.meegid.2008.10.002","article-title":"Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.","volume":"9","author":"Dumans","year":"2009","journal-title":"Infect Genet Evol"},{"key":"R25-20230913","first-page":"60","article-title":"HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy.","volume":"15","author":"Angelis","year":"2011","journal-title":"Braz J Infect Dis"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/aid.2009.0164","article-title":"Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.","volume":"26","author":"Towler","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/aid.2009.0003","article-title":"In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.","volume":"25","author":"Church","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R28-20230913","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/aid.2012.0283","article-title":"Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.","volume":"29","author":"Musiime","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R29-20230913","first-page":"290","article-title":"Clinical, immunologic and virologic follow-up in perinatally HIV-1 infected children and adolescents from the Madrid Cohort with triple-class antiretroviral drug resistant viruses.","volume":"15","author":"Rojas","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R30-20230913","doi-asserted-by":"crossref","first-page":"e83337","DOI":"10.1371\/journal.pone.0083337","article-title":"Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of circulating recombinant form (CRF) 50_A1D.","volume":"9","author":"Foster","year":"2014","journal-title":"PLoS One"},{"key":"R31-20230913","doi-asserted-by":"crossref","first-page":"E485","DOI":"10.1111\/1469-0691.12011","article-title":"Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.","volume":"18","author":"Monge","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R32-20230913","first-page":"e9071","article-title":"Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations.","volume":"7","author":"Monge","year":"2012","journal-title":"PLoS One"},{"key":"R33-20230913","article-title":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios-AEMPS.","year":"2016"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1086\/521683","article-title":"Increasing HIV-1 genetic diversity in Europe.","volume":"196","author":"Thomson","year":"2007","journal-title":"J Infect Dis"},{"key":"R36-20230913","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2010.10.008","article-title":"Sensitivity of seven HIV subtyping tools differs among subtypes\/recombinants in the Spanish cohort of na\u00efve HIV-infected patients (CoRIS).","volume":"89","author":"Yebra","year":"2011","journal-title":"Antiviral Res"},{"key":"R37-20230913","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1128\/JCM.05798-11","article-title":"Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-na\u00efve HIV-infected patients (CoRIS) are due to recombinant viruses.","volume":"50","author":"Yebra","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R38-20230913","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/157016208785132455","article-title":"Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain.","volume":"6","author":"Holgu\u00edn","year":"2008","journal-title":"Curr HIV Res"},{"key":"R39-20230913","doi-asserted-by":"crossref","first-page":"10755","DOI":"10.1128\/JVI.00454-11","article-title":"Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis.","volume":"85","author":"Gonz\u00e1lez-Alba","year":"2011","journal-title":"J Virol"},{"key":"R40-20230913","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1093\/jac\/dkq380","article-title":"Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006\/2007 in France.","volume":"65","author":"Descamps","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R41-20230913","doi-asserted-by":"crossref","first-page":"e99390","DOI":"10.1371\/journal.pone.0099390","article-title":"Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades.","volume":"9","author":"Neogi","year":"2014","journal-title":"PLoS One"},{"key":"R42-20230913","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-4690-7-25","article-title":"The role of recombination in the emergence of a complex and dynamic HIV epidemic.","volume":"7","author":"Zhang","year":"2010","journal-title":"Retrovirology"},{"key":"R43-20230913","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1089\/aid.2009.0311","article-title":"Identification of a new HIV type 1 circulating BF intersubtype recombinant form (CRF47_BF) in Spain.","volume":"26","author":"Fern\u00e1ndez-Garc\u00eda","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R44-20230913","doi-asserted-by":"crossref","first-page":"e0148549","DOI":"10.1371\/journal.pone.0148549","article-title":"Identification of an HIV-1 BG intersubtype recombinant form (CRF73_BG), partially related to CRF14_BG, which is circulating in Portugal and Spain.","volume":"11","author":"Fern\u00e1ndez-Garc\u00eda","year":"2016","journal-title":"PLoS One"},{"key":"R45-20230913","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1097\/QAD.0b013e3283632e0c","article-title":"Characterization of CRF56_cpx, a new circulating B\/CRF02\/G recombinant form identified in MSM in France.","volume":"27","author":"Leoz","year":"2013","journal-title":"AIDS"},{"key":"R46-20230913","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.meegid.2014.02.007","article-title":"Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men.","volume":"23","author":"Simonetti","year":"2014","journal-title":"Infect Genet Evol"},{"key":"R47-20230913","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/aid.2009.0201","article-title":"Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO Cohort.","volume":"26","author":"Galimand","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R48-20230913","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/pr.2016.183","article-title":"Evaluation of 4 virologic tests using DBS for HIV-1 early infant diagnosis.","volume":"81","author":"Alvarez","year":"2017","journal-title":"Pediatr Res"},{"key":"R49-20230913","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1128\/JCM.02414-07","article-title":"Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep\/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants.","volume":"46","author":"Holgu\u00edn","year":"2008","journal-title":"J Clin Microbiol"},{"key":"R50-20230913","doi-asserted-by":"crossref","first-page":"1000123","DOI":"10.4172\/2324-8955.1000123","article-title":"HIV-1 RNA quantification from Dried Blood Spots and plasma using the Siemens VERSANT\u00ae HIV-1 RNA 1.0 Assay (kPCR).","volume":"3","author":"Alvarez","year":"2014","journal-title":"J Virol Antivir Res"},{"key":"R51-20230913","first-page":"150","article-title":"HIV-1 RNA quantification in CRF02_AG HIV-1 infection: too easy to make mistakes.","volume":"39","author":"Tatarelli","year":"2016","journal-title":"New Microbiol"},{"key":"R52-20230913","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1469-0691.2010.03300.x","article-title":"Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays.","volume":"16","author":"Peeters","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"R53-20230913","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jinf.2012.10.026","article-title":"Implications of HIV diversity for the HIV-1 pandemic.","volume":"66","author":"Hemelaar","year":"2013","journal-title":"J Infect"},{"key":"R54-20230913","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1097\/QAD.0b013e3283636179","article-title":"The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.","volume":"27","author":"Mackie","year":"2013","journal-title":"AIDS"},{"key":"R55-20230913","first-page":"212","article-title":"Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.","volume":"10","author":"Mart\u00ednez-Cajas","year":"2008","journal-title":"AIDS Rev"},{"key":"R56-20230913","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/QAI.0b013e31824a0628","article-title":"Does genetic diversity of HIV-1 non-B subtypes differentially impact disease progression in treatment-naive HIV-1-infected individuals? A systematic review of evidence: 1996-2010.","volume":"59","author":"Pant Pai","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R57-20230913","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.","volume":"88","author":"deCamp","year":"2014","journal-title":"J Virol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201803000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:11:33Z","timestamp":1694628693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201803000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001760","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}